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Opicapone as Adjunct to Levodopa Therapy in Patients
With Parkinson Disease andMotor Fluctuations
A Randomized Clinical Trial
Andrew J. Lees, MD; Joaquim Ferreira, MD; Olivier Rascol, MD;Werner Poewe, MD; José-Francisco Rocha, BSc; Michelle McCrory, MSc;
Patricio Soares-da-Silva, MD; for the BIPARK-2 Study Investigators
IMPORTANCE CatecholO-methyltransferase (COMT) inhibitors are an established treatment
for end-of-dosemotor fluctuations associated with levodopa therapy in patients with
Parkinson disease (PD). Current COMT inhibitors carry a high risk for toxic effects to hepatic
cells or showmoderate improvement. Opicapone was designed to be effective without the
adverse effects.
OBJECTIVE To evaluate the efficacy and safety of 25- and 50-mg/d dosages of opicapone
compared with placebo as adjunct to levodopa therapy in patients with PD experiencing
end-of-dosemotor fluctuations.
DESIGN This phase 3 international, multicenter outpatient study evaluated a 25- and a
50-mg/d dosage of opicapone in a randomized, double-blind, 14- to 15-week,
placebo-controlled clinical trial, followed by a 1-year open-label phase during which all
patients received active treatment with opicapone. Patients with PDwho experienced signs
of end-of-dose deterioration and had amean total awake off-time (state of akinesia or
decreasedmobility) of at least 1.5 hours, not includingmorning akinesia, were enrolled. Data
were collected fromMarch 18, 2011, through June 25, 2013. Data from the evaluable
population were analyzed from July 31, 2013, to July 31, 2014.
MAIN OUTCOMES ANDMEASURES The primary efficacy outcome of the double-blind phase
was the change from baseline in absolute off-time vs placebo based on patient diaries. The
open-label phase focused onmaintenance of treatment effect in off-time.
RESULTS A total of 427 patients (258men [60.4%] and 169women [39.6%]; mean [SD] age,
63.1 [8.8] years) were randomized to a 25-mg/d (n = 129) or a 50-mg/d (n = 154) dosage of
opicapone or to placebo (n = 144). Of these, 376 patients completed the double-blind phase
and entered the open-label phase, of whom 286 completed 1 year of open-label treatment.
At the end of the double-blind phase, the least squares mean change (SE) in off-time was
−64.5 (14.4) minutes for the placebo group, −101.7 (14.9) minutes for the 25-mg/d opicapone
group, and −118.8 (13.8) minutes for the 50-mg/d opicapone group. The adjusted treatment
difference vs placebo was significant for the 50-mg/d opicapone group (treatment effect,
−54.3 [95% CI, −96.2 to −12.4] minutes; P = .008), but not for the 25-mg/d opicapone group
(treatment effect, −37.2 [95% CI, −80.8 to 6.4] minutes; P = .11). The off-time reduction was
sustained throughout the open-label phase (−126.3 minutes at 1-year open-label end point).
Themost common adverse events in the opicapone vs placebo groups were dyskinesia,
constipation, and dry mouth. Fifty-one patients (11.9%) discontinued from the study during
the double-blind phase.
CONCLUSIONS AND RELEVANCE Treatment with a 50-mg once-daily dose of opicaponewas
associated with a significant reduction in mean daily off-time in levodopa-treated patients
with PD andmotor fluctuations, and this effect is maintained for at least 1 year. Opicapone
was safe and well tolerated.
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C atechol O-methyltransferase (COMT) inhibitors are anestablished treatment for motor fluctuations associ-ated with levodopa therapy. Two COMT inhibitors are
currentlyavailable for clinicaluse.Tolcaponewaswidelyused,
but owing to the risk for potentially fatal hepatic toxic ef-
fects, its clinical usenowrequires regular liver functionmoni-
toring and is only considered in patients who have failed to
respond to entacapone.1,2 Entacapone is considered safer, but
gains in daily on-time (the state of adequate control of symp-
toms) are moderate (mean of 0.6 hours across randomized
trials3). Thus, amore effectiveCOMT inhibitor that canbeeas-
ily used in routine clinical practice is needed.4
Opicaponewas rationally designed toprovidehighCOMT
inhibitory potency and avoid toxic effects to cells.5 Opica-
ponehas averyhighbindingaffinity that translates into a slow
complex dissociation rate constant and a long duration of ac-
tion that allows once-daily dosing.6
Methods
Study Conduct
This randomizedclinical double-blindplacebo-controlled trial
evaluated the efficacy and safety of opicapone (25 and 50mg
oncedaily) as adjunct to levodopa therapy, followedbya 1-year
open-label phase during which all patients received opica-
pone. The studywas conducted fromMarch 18, 2011, through
June 25, 2013. The double-blind phase was conducted at 71
centers across 12 countries (region 1: Belgium, United King-
dom, and Israel; region 2: Estonia, Czech Republic, and Rus-
sia; region 3: South Africa, Australia, and South Korea, region
4: India; region 5: Argentina and Chile), and the open-label
phasewas conducted at 64 sites (excluding those in theCzech
Republic). Institutional reviewboardsat theparticipating sites
approved the protocol (available in Supplement 1); a list of in-
stitutional reviewboards is available ineTable 1 inSupplement
2), and the trial was conducted in accordance with the decla-
ration of Helsinki7 and International Conference on Harmo-
nization Good Clinical Practice Guidelines.8 All patients pro-
vided written informed consent.
Study Population
Adult men or women (aged 30-83 years) were eligible if they
had a clinical diagnosis of Parkinson disease (PD)9 for at least
3 years, a Hoehn-Yahr stage10 of 1 to 3 (on stage, or mild uni-
lateraldiseasetomildtomoderatebilateraldisease),andat least
a 1-year history of clinical improvementwith levodopa and/or
dopa decarboxylase inhibitor (levodopa/DDCI) therapy. Pa-
tients had to have received a stable optimized regimen of 3 to
8 daily doses of levodopa/DDCI therapy and other PD medi-
cations for at least 4 weeks before screening. All patients had
signs of end-of-dose deterioration for at least 4 weeks before
screening,with amean total awake off-time (state of akinesia
or decreased mobility) of at least 1.5 hours, excluding morn-
ing akinesia. Patients had to keep reliable diaries; only pa-
tients who had filled-in self-rating diary charts in accordance
with instructions andhadnomore than 3 errors per day in the
3 days before the baseline visit were randomized.
Keyexclusioncriteria includedadyskinesiadisability score
greater than3on item33of theUnifiedParkinson’sDiseaseRat-
ing Scale (UPDRS) (range, 0-4, with higher scores indicating
severely or completely disabling dyskinesia),11 severe and/or
unpredictable off-periods, previous surgery or deep brain
stimulation for PD, history of neuroleptic malignant syn-
drome or nontraumatic rhabdomyolysis, or anymedical con-
dition that might interfere with assessments, including de-
mentia, clinically significant cardiovascular disease, or
psychiatric illness. Patients with a history of liver disease or
who had abnormal levels of liver enzymes (alanine amino-
transferase and/or aspartate aminotransferase) more than
2 times the upper normal limit at the screening visit were
also excluded. Concomitant stable treatment for PD was al-
lowed, with the exception of entacapone, tolcapone, and
apomorphine hydrochloride (withdrawn ≥1 month before
screening). Treatment with neuroleptics, venlafaxine hydro-
chloride, monoamine oxidase inhibitors (except selegiline
hydrochloride, ≤10 mg/d in oral formulation or 1.25 mg/d in
buccal formulation, and rasagilinemesylate, ≤1 mg/d), or an-
tiemetics with antidopaminergic action (except domperi-
done) was prohibited during the study (withdrawn ≥1 month
before screening).
Study Design
Eligible patients were randomized at baseline to the double-
blind phase using a computer-generated scheme (adminis-
tered by Cenduit, LLC) in a ratio of 1:1:1 to the addition of oral
opicapone, 25 mg/d or 50 mg/d, or matching placebo using
blocks stratifiedby region (Figure). Dependingon theneed for
levodopa/DDCI therapy adjustment, the first efficacy assess-
ment could occur from 3 to 4 weeks after baseline. Thereaf-
ter,double-blindassessmentsoccurredat4-week intervals,and
the total duration of the double-blind phase could be 14 to 15
weeks. The open-label phase began the day after completing
the double-blind phase and continued until the patient had
completed 52 weeks of open-label treatment.
StudyMedications
Studymedicationwas taken in the evening, at least 1 hour af-
ter the last dose of levodopa/DDCI. In thedouble-blindphase,
reductions in the daily dose (but not frequency) of levodopa/
DDCI could be made between baseline and 3 to 4 weeks after
Key Points
Question How effective and safe is opicapone when given as
adjunct to levodopa therapy in patients with Parkinson disease
who experiencemotor fluctuations?
Findings In this randomized clinical trial of 427 patients, a
50-mg/d but not a 25-mg/d dosage of opicapone was associated
with a significant reduction in off-time vs placebo (treatment
effect, −54.31 minutes). This off-time reduction was sustained
throughout the 1-year open-label extension study.
Meaning The efficacy and safety of a 50-mg/d dosage of
opicapone compares well with currently available catechol
O-methyltransferase inhibitors.
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baseline according to the clinical response but were not per-
mitted thereafter. Patients started open-label treatment with
the 25-mg/d dosage of opicapone, which could be titrated up
to 50mg/d if greater symptomatic controlwas required. If un-
acceptable dopaminergic adverse events appeared, investiga-
tors could first lower the levodopadosage and then, if thiswas
not sufficient, the opicapone dosage could be reduced. Doses
of levodopaandopicaponehad to remainstableduring the last
month of study.
Assessments
Primary and key secondary efficacy variables were assessed
using24-hourpatientdiaries12 inwhichpatients recorded their
status as off, on with troublesome dyskinesia, on with non-
troublesome dyskinesia, onwithout dyskinesia, or asleep for
every30-minute intervalduring theday for 3 consecutivedays
before each visit. Patients were trained to identify whether a
30-minute period was spent as mostly on or mostly off. Off-
and on-times at each visit were calculated as themean of the
3 precedingdiary days. Theproportion of off- andon-time re-
sponders per treatment group (proportion of patients with a
decrease of ≥1 hour off-time or an increase of ≥1 hour on-
time)was also analyzed. Patients also underwent assessment
in theonstateusing theUPDRS,11withpart II (activitiesofdaily
living) completed in the on and off states. Additional out-
come measures were the Parkinson’s Disease Sleep Scale
(PDSS),13 the 39-item Parkinson’s Disease Questionnaire
(PDQ-39),14 theNon-Motor SymptomsScale (NMSS),15 and the
clinician’s and patient’s Clinical Global Impression of Change
(CGI-C and PGI-C, respectively).16
An independent Data Safety Monitoring Board periodi-
cally received partially blinded safety data (an unblinded
Figure. Study CONSORTDiagram
485 Patients underwent screening
58 Excluded
33 Ineligibility
3 Adverse event
2 Noncompliance
2 Lost to follow-up
2 Other
11 Withdrawal of consent
5 Sponsor’s discretion
81 Discontinued
1 Lost to follow-up
4 Noncompliance
2 Protocol violation
10 Withdrew consent
22 Sponsor decision
1 Physician decision
4 Other
32 Adverse event
5 Lack of efficacy
144 Randomized to
placebo
130 Completed
double-blind period
14 Discontinued
1 Ineligible
1 Withdrew consent
2 Other
1 Lost to follow-up
9 Adverse event
135 FAS
129 Randomized to
opicapone, 25 mg/d
367 Entered open-label
period
2 Who had terminated the double-blind
phase early owing to lack of study 
medication included
286 Completed 
118 Completed
double-blind period
11 Discontinued
5 Adverse event
3 Lack of efficacy
3 Withdrew consent
125 FAS
154 Randomized to
opicapone, 50 mg/d
128 Completed
double-blind period
26 Discontinued
17 Adverse event
2 Withdrew consent
3 Other
3 Noncompliance
1 Protocol violation
147 FAS
427 Randomized
FAS indicates full-analysis set.
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biostatisticianattendedmeetings toansweranyquestions).Ad-
verse events, vital signs, and safety laboratory tests were as-
sessed throughout the study. In addition, the Columbia–
Suicide Severity Rating Scale17 and the Modified Minnesota
Impulsive Disorders Interview18 were also assessed.
Statistical Analyses
Data were analyzed from July 1, 2013, to July 1, 2014. Popula-
tions undergoing analysis included the double-blind full-
analysis set of all randomizedpatientswho tookat least 1 dose
of study medication and had at least 1 postbaseline off-time
assessment; theopen-label full-analysis set of all patientswho
received at least 1 dose of study treatment in the open-label
period and had at least 1 off-time efficacy assessment in the
open-label period; and the safety set of all patients who re-
ceived at least 1 dose of study medication.
The primary efficacy variable for the double-blind phase
was the change frombaseline in absolute off-time,whichwas
analyzed in the double-blind full-analysis set using an analy-
sis of covariancewith treatment group and region included as
factors and baseline off-time as a covariate. A Dunnett α level
adjustment was used for the comparison of each active dose
group with placebo, and the last observation carried forward
method was used to handle missing diary data.
Toavoid inflationof type Ierrors,keysecondaryendpoints
in the double-blind phasewere analyzed according to the fol-
lowing predefined hierarchy: the proportions of patients
achieving at least a 1-hour reduction in absolute off-time and
the proportions of patients achieving at least a 1-hour in-
crease inabsoluteon-timeat theendof thedouble-blindphase;
change from baseline to the end of the double-blind phase in
UPDRSmotor scores; and change from baseline to the end of
thedouble-blindphase in absolute total on-time andpercent-
age of off-time. A nonsignificant result in any of these hierar-
chical testsmeant thatall testsperformedbelowthatpointwere
considered exploratory. Other scale-based efficacy outcomes
were the change from baseline to the end of the double-blind
phase inUPDRS,PDSS,PDQ-39, andNMSSscoresandthemean
CGI-C and PGI-C scores at the end of the double-blind phase.
The proportion of off- and on-time responders per treatment
group was compared using a Cochran-Mantel-Haenszel test
withpooledcountryas strata.TheCGI-CandPGI-Cscoreswere
analyzed using a nonparametric van Elteren test19 for treat-
ment effect stratifiedbypooled country.Other secondaryout-
comes were analyzed in a similar manner to the primary effi-
cacy variable.
Maintenance of treatment effect during the open-label
phase was analyzed through the change from the start to the
end of the open-label phase of absolute off-time using a lin-
earmodelwith pooled country included as a factor. All safety
analysesweredescriptive andperformedusing the safety set.
Determination of Sample Size
Assuming that the mean reductions in off-time would be 90
and 105 minutes for the opicapone dosages and 30 minutes
for the placebo dosage,20 a total of 135 evaluable patients in
each arm of the double-blind full-analysis set was estimated
to ensure at least 95% power to confirm a treatment effect vs
placebo in the most efficacious opicapone dosage group and
at least 85% power to confirm a treatment effect in the least
efficacious opicapone dosage group.
Results
Patient Disposition
Of the 485 patients screened, 427were enrolled and random-
ized (258men[60.4%]and169women[39.6%];mean[SD]age,
63.1 [8.8] years). Of these, 376 (88.1% of randomized pa-
tients) completed thedouble-blindphase (Figure).Overall, 367
patients who completed the double-blind phase, including 2
patients who had discontinued the double-blind phase early
owing to lack of study medication, entered the open-label
phase, and 286 of these (77.9%) completed 1 year of open-
label treatment. The most common reason for study discon-
tinuation in both phases was adverse events.
Demographics, Baseline Characteristics, and PDMedications
Mostbaselinecharacteristicswerecomparablebetweengroups
(Table 1); however, the placebo group had slightly fewermale
andmore Asian patients comparedwith the active treatment
groups. Patients had amean (SD) disease duration (time since
diagnosis) ranging from7.7 (3.7) to8.5 (4.4) years andhadbeen
receiving levodopa for amean (SD)of6.8 (3.6) to7.2 (4.3) years.
Themean (SD) daily levodopadosewas 700 (312) to 806 (398)
mg and themean (SD) duration of wearing off was 3.0 (2.3) to
3.2 (3.3) years.
Primary Efficacy Analysis in the Double-Blind Phase
All groupsachieved reductions inoff-timevsbaseline (eFigure
in Supplement 2). At the end of the double-blind phase, the
mean (SD) change in off-timewas −64.5 (14.4)minutes for the
placebo group, −101.7 (14.9) minutes for the 25-mg/d opica-
pone group, and −118.8 (13.8) minutes for the 50-mg/d opica-
pone group. The adjusted least squares mean change from
baseline inabsoluteoff-timeat studyendwas largest in the50-
mg/dopicaponegroup.Theadjustedtreatmentdifferencecom-
pared with the placebo group was significant for the 50-mg/d
opicapone group (treatment effect [SD], −54.3 [18.9] minutes;
95% CI, −96.2 to −12.4 minutes; P = .008), but not for the 25-
mg/d opicapone group (treatment effect [SD], −37.2 [19.6]
minutes; 95% CI, −80.8 to 6.4minutes; P = .11).
Secondary Outcomes in the Double-Blind Phase
Secondary efficacy findings are summarized inTable 2. Com-
pared with the placebo group with off-time response rates of
68 (50.4%) and on-time response rates of 61 (45.2%), the pro-
portion of responders in the full-analysis set was signifi-
cantly higher among the off-time responders in the 25-mg/d
opicapone group (78 [62.4%]; P = .04) and 50-mg/d opica-
pone group (97 [66.0%]; P = .009) and among on-time
responders in the 25-mg/d opicapone group (79 [63.2%];
P = .004) and the 50-mg/d opicapone group (91 [61.9%];
P = .006).Under thehierarchical procedure, thenext key sec-
ondary variable to be analyzed was the change from baseline
to theendofdouble-blindphase inUPDRSmotor scores.Mean
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(SE) changes inmotor function were small and similar across
all groups (−2.1 [0.5] for the placebo group; −2.9 [0.5] for the
25-mg/d opicapone group [P = .26]; −2.0 [0.5] for
the50-mg/dopicaponegroup [P = .82]); thus, according to the
hierarchical procedure, all analyses from this point were
considered exploratory.
Other diary-reported secondary efficacy findings sup-
ported thoseof theprimary analysis and confirmed that treat-
ment with opicapone resulted in larger increases in mean
(SE) least squares absolute on-time (58.7 [14.2]minutes in the
placebo group, 104.1 [14.7] minutes in the 25-mg/d opica-
pone group [P = .02], and 111.3 [13.7] minutes in the 50-mg/d
opicaponegroup [P = .005]) and larger reductions in themean
(SE) least squares percentage of off-time (−6.7% [1.4%] in the
placebogroup, −11.0% [1.5%] in the 25-mg/dopicaponegroup
[P = .03], and −12.1% [1.4%] in the 50-mg/d opicapone group
[P = .004]) (Table 2). Most of the gain of on-time with opica-
pone was without troublesome dyskinesia; increases in on-
time with troublesome dyskinesia were not significantly dif-
ferent from the placebo group (11.2 minutes) for the 25-mg/d
opicapone group (19.4 minutes; P = .49) or the 50-mg/d opi-
capone group (25.6minutes;P = .21) (eTable 2 in Supplement
2). The UPDRS total (reduction of −3.5 to −4.4 points), UPDRS
activitiesofdaily living in theoff state (reductionof−1.9 to−2.5
points), UPDRS activities of daily living in the on state (reduc-
tionof −0.5 to−1.0points), PDSS (increase of 2.3 to 5.1 points),
PDQ-39 (reductionof −2.6 to−4.8points),NMSS (reductionof
−2.0 to −5.2 points), CGI-C (increase of 3.2 to 3.5 points), and
PGI-C (increaseof 3.2 to 3.5points) assessments showedsome
improvements across all treatment groups, with no signifi-
cant differences among them.
Maintenance of Treatment Effect in the Open-Label Phase
Off-time reduction from the double-blind baseline was sus-
tainedduring theopen-label phase; theadjustedmeanchange
from the start to the end of the open-label phase in off-time
was −18.31 (95% CI, −43.56 to 6.95) minutes. Mean (SD) total
on-time increased by 24.9 (156.4) minutes, and this increase
Table 1. Demographics and Baseline Disease Characteristics at Entry to the Double-Blind Phase
Parameter
Treatment Group, Mean (SD)
Placebo
(n = 135)
Opicapone Dosage
25 mg/d
(n = 125)
50 mg/d
(n = 147)
Male, No. (%) 71 (52.6) 82 (65.6) 89 (60.5)
Age, y 61.5 (8.9) 62.5 (8.5) 65.5 (8.4)
Race/ethnicity, No. (%)
Whitea 89 (65.9) 90 (72.0) 115 (78.2)
Asian 42 (31.1) 29 (23.2) 31 (21.1)
Other 3 (2.2) 6 (4.8) 1 (0.7)
Time since PD diagnosis, y 7.7 (3.7) 8.5 (4.4) 8.2 (4.5)
Time since levodopa therapy initiation, y 6.8 (3.6) 7.2 (4.3) 7.1 (4.7)
Time since onset of wearing off, y 3.0 (2.3) 3.2 (2.8) 3.2 (3.3)
Modified Hoehn-Yahr stage (on)b 2.4 (0.6) 2.3 (0.7) 2.4 (0.5)
Total UPDRS scorec 31.5 (17.0) 30.8 (16.9) 31.7 (17.6)
UPDRS Part III (motor) scored 22.5 (12.0) 21.5 (12.0) 22.5 (12.3)
Off-time
Absolute time, h 6.1 (2.3) 6.2 (2.2) 6.3 (2.2)
Total awake time, % 37.5 (13.8) 38.8 (13.2) 38.9 (12.8)
On-time without or with nontroublesome dyskinesia
Absolute time, h 9.6 (2.4) 9.2 (2.3) 9.4 (2.2)
Total awake time, % 59.0 (14.5) 57.4 (12.9) 57.9 (13.0)
On-time with troublesome dyskinesia
Absolute time, h 0.6 (1.4) 0.6 (1.3) 0.5 (1.2)
Total awake time, % 3.5 (8.7) 3.8 (8.5) 3.2 (7.2)
Presence of dyskinesia, No. (%) 72 (53.3) 65 (52.0) 80 (54.4)
Levodopa dosage, mg/d 714 (338) 806 (398) 700 (312)
DDCI used with levodopa, No. (%)e
Carbidopa 83 (61.5) 87 (69.6) 91 (61.9)
Benserazide 60 (44.4) 43 (34.4) 65 (44.2)
Adjunct medications, No. (%)f
Dopamine agonist 98 (72.6) 83 (66.4) 102 (69.4)
Monoamine oxidase type B inhibitor 26 (19.3) 23 (18.4) 32 (21.8)
Anticholinergic 13 (9.6) 20 (16.0) 14 (9.5)
Amantadine 29 (21.5) 29 (23.2) 28 (19.0)
Abbreviations: DDCI, dopa
decarboxylase inhibitor;
PD, Parkinson disease;
UPDRS, Unified Parkinson’s Disease
Rating Scale.
a Data were missing for one patient in
the placebo group.
b Stages range from0 to 5, with
higher stages indicating worse
motor function.
c Scores range from0 to 176, with
higher scores indicating worse
symptom severity.
d Scores range from0 to 108, with
higher scores indicating worse
motor symptom severity.
e Some patients used both
formulations.
f Patients could receive multiple
adjunct medications.
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was again mostly owing to an increase of on-time without or
withnontroublesomedyskinesia.During theopen-labelphase,
mean (SD) on-timewith troublesomedyskinesia increasedby
6.0 (129.1) minutes.
Levodopa Dosage Reductions
At the endof thepermitted adjustment period (first 2-3weeks
of the double-blind phase), the overall levodopa dose de-
creasedby ameanof 47.2mg in the 25-mg/dopicapone group
and 29.3mg in the 50-mg/d opicapone group comparedwith
9.4 mg in the placebo group. At the end of the double-blind
phase, the mean levodopa doses were 762.5 mg in the 25-
mg/d opicapone group, 674.3 mg in the 50-mg/d opicapone
group, and 713.3 mg in the placebo group.
Table 2. Key Secondary Efficacy Results in Hierarchical Order
in Double-Blind Phase
Variable
Treatment Group
Placebo
(n = 135)
Opicapone Dosage
25 mg/d
(n = 125)
50 mg/d
(n = 147)
Key Secondary End Points in Hierarchical Order
Responder rate of off-time reduction of ≥1 h at end
of double-blind phase
No. (%) 68 (50.4) 78 (62.4) 97 (66.0)
OR (95% CI) NA 1.7 (1.0 to 2.8) 1.9 (1.2 to 3.1)
P value vs
placebo
NA .04 .009
Responder rate of on-time increase of ≥1 h at end
of double-blind phase
No. (%) 61 (45.2) 79 (63.2) 91 (61.9)
OR (95% CI) NA 2.1 (1.3 to 3.4) 2.0 (1.2 to 3.2)
P value vs
placebo
NA .004 .006
Change from baseline to end of double-blind phase
in UPDRS Part III scores
LS, mean (SE) −2.1 (0.5) −2.9 (0.5) −2.0 (0.5)
Treatment effect
vs placebo
(95% CI)
NA −0.8 (−2.3 to 0.6) 1.6 (−1.2 to 1.5)
P value NA .26 .82
Change from baseline to end of double-blind phase in absolute total on-time,
mina
LS, mean (SE) 58.7 (14.2) 104.1 (14.7) 111.3 (13.7)
Treatment effect
vs placebo
(95% CI)
NA 45.4 (7.1 to 83.8) 52.6 (15.8 to 89.3)
P value NA .02 .005
Change from baseline to end of double-blind phase
in off-time, %b
LS, mean (SD) −6.7 (1.4) −11.0 (1.5) −12.1 (1.4)
Treatment effect
vs placebo
(95% CI)
NA −4.3 (−8.2 to −0.4) −5.5 (−9.2 to −1.7)
P value NA .03 .004
Scale-Based Outcome Measures From Baseline to End of Double-Blind Phase
UPDRS total scorec
No. of patients 122 114 127
LS, mean (SE) −3.5 (0.7) −4.4 (0.7) −3.5 (0.7)
P value vs
placebo
NA .37 .45
UPDRS Part II
(ADL) score (off)d
No. of patients 122 114 127
LS, mean (SE) −1.9 (0.4) −2.5 (0.4) −2.2 (0.3)
P value vs
placebo
NA .24 .56
(continued)
Table 2. Key Secondary Efficacy Results in Hierarchical Order
in Double-Blind Phase (continued)
Variable
Treatment Group
Placebo
(n = 135)
Opicapone Dosage
25 mg/d
(n = 125)
50 mg/d
(n = 147)
UPDRS Part II
(ADL) score (on)d
No. of patients 122 114 127
LS, mean (SE) −1.0 (0.3) −1.1 (0.3) −0.5 (0.2)
P value vs
placebo
NA .69 .18
PDSS scoree
No. of patients 133 123 147
LS, mean (SE) 5.1 (1.8) 2.5 (1.9) 2.3 (1.7)
P value vs
placebo
NA .29 .23
PDQ-39 scoref
No. of patients 118 112 124
LS, mean (SE) −4.8 (1.0) −2.6 (1.0) −4.4 (1.0)
P value vs
placebo
NA .12 .78
NMSS scoreg
No. of patients 126 121 147
LS, mean (SE) −5.2 (1.6) −2.0 (1.6) −4.9 (1.5)
P value vs
placebo
NA .13 .88
CGI-C scoreh
No. 134 124 146
Mean (SD) 3.4 (0.3) 3.2 (0.3) 3.5 (0.2)
P value vs
placebo
NA .11 .83
PGI-C scoreh
No. 134 124 146
Mean (SD) 3.4 (1.2) 3.2 (1.4) 3.5 (1.3)
P value vs
placebo
NA .08 .82
Abbreviations: ADL, activities of daily living; CGI-C, clinician’s Clinical Global
Impression of Change; LS, least squares; NA, not applicable; NMSS, Non-Motor
Symptoms Scale; OR, odds ratio; PDQ-39, Parkinson’s Disease Questionnaire;
PDSS, Parkinson’s Disease Sleep Scale; PGI-C, patient’s Clinical Global
Impression of Change; UPDRS, Unified Parkinson’s Disease Rating Scale.
a Considered exploratory outcome under the hierarchical analysis. On-time was
assessed as the sum of all on-time (including on with troublesome dyskinesia,
with nontroublesome dyskinesia, and without dyskinesia).
b Calculated as the sum inminutes from 30-minute periods classified as off
divided by the total time awake.
c Scores range from0 to 176, with higher scores indicating worse symptom
severity.
d Scores range from0 to 52, with higher scores indicating greater effect.
e Scores range from0 to 150, with higher scores indicating lower disability due
to sleep problems.
f Scores range from0 to 100, with higher scores indicating worse perceived
health status.
g Scores range from0 to 360, with higher scores indicating greater disability
due to nonmotor symptoms.
h Scores range from 1 to 7, with 1 indicating very much improved; 2, much
improved, 3, minimally improved; 4, no change; 5, minimally worse; 6, much
worse; and 7, very much worse.
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During the open-label phase, the mean daily levodopa
dose was maintained below the baseline value, with 213 of
339 patients (62.8%) continuing to receive the same dose of
levodopa. The mean (SD) number of daily levodopa doses
also remained stable during this phase, ranging from 4.69
(1.54) to 4.76 (1.56) during the course of the year. Overall, 40
of 339 patients (11.8%) had a reduction of the levodopa dose
between the open-label baseline and the end of study. At
the end of the open-label phase, the mean levodopa dose
was 693.9 mg, a decrease of 35.6 mg vs the double-blind
baseline.
Safety and Tolerability
More than half of patients in each group (total, 282 of 411 pa-
tients [68.6%]) experienced at least 1 adverse event (Table 3),
whichwasusuallymildormoderate in intensity. In thedouble-
blindphase, themost commonadverseeventsoccurring in the
opicaponegroups comparedwith theplacebogroupweredys-
kinesia, constipation, and drymouth. Most of the dyskinesia
events (58 [75.3%]) across all groups occurred in patients al-
ready experiencing dyskinesia at baseline. Serious adverse
events were observed in 18 patients (4.4%) in the double-
blindphase and in40of 353 patients (11.3%) in the open-label
phase (Table 3). One death (due to pneumonia in the placebo
group) occurred in the double-blind phase and 5 deaths (due
to septic shock, small cell lung cancer, cerebral hemorrhage
after traumatic brain injury, cerebral hemorrhage, and an un-
known cause) occurred in the open-label phase.
In the double-blind phase, discontinuations due to ad-
verse events were more frequent for the 50-mg/d opicapone
group (17of 150 [11.3%]) than for the25-mg/dopicaponegroup
(5of 125 [4.0%])or theplacebogroup(9of 136 [6.6%]) (Table4).
Themost commonadverse event leading to studydiscontinu-
ation was dyskinesia (4 patients in the 50-mg/d opicapone
group; 1 patient in the placebo group; and none in the 25-
mg/dopicaponegroup).Other adverse events leading to study
discontinuation were reported in 26 patients (6.1%); no pa-
tient discontinued study participation owing to diarrhea.
Thirty-two patients (9.1%) discontinued because of an ad-
verseeventduring theopen-labelphase. In thisphase, themost
common treatment-related reasons for study discontinua-
tions were dopaminergic events (3 patients [0.8%] for dyski-
nesia, 3 [0.8%] for hallucinations, and 1 [0.3%] for orthostatic
hypotension) and aggravation of PD (2 [0.5%]).
Norelevant liver functionfindingsoccurred ineitherphase.
The Columbia–Suicide Severity Rating Scale showed no ef-
fect on suicidality. Impulsive disorders as screened with the
Modified Minnesota Impulsive Disorders Interview were re-
ported in few patients.
Table 3. Summary of Treatment-Emergent Adverse Events
in Open-Label Phase
Type of Adverse Event No. (%) of Patients
All
≥1 268 (75.9)
Serious 40 (11.3)
Leading to discontinuation 32 (9.1)
Death 5 (1.4)
Affecting >5% in any arm
Dyskinesia 76 (21.5)
PD aggravated 60 (17.0)
Fall 32 (9.1)
Blood creatine phosphokinase level increased 26 (7.4)
Insomnia 20 (5.7)
Orthostatic hypotension 19 (5.4)
Abbreviation: PD, Parkinson disease.
Table 4. Summary of Treatment-Emergent Adverse Events in Double-Blind Phase
Type of Adverse Event
No. (%) of Patients
Placebo
(n = 136)
Opicapone Dosage
25 mg/d
(n = 125)
50 mg/d
(n = 150)
All
≥1 87 (64.0) 87 (69.6) 108 (72.0)
Serious 5 (3.7) 4 (3.2) 9 (6.0)
Leading to discontinuation 10 (7.4) 5 (4.0) 18 (12.0)
Death 1 (0.7) 0 0
Affecting >5% in any arm
Dyskinesia 11 (8.1) 30 (24.0) 36 (24.0)
Constipation 2 (1.5) 12 (9.6) 10 (6.7)
Dry mouth 1 (0.7) 13 (10.4) 6 (4.0)
Blood creatine phosphokinase level increased 5 (3.7) 5 (4.0) 12 (8.0)
PD aggravated 7 (5.1) 9 (7.2) 6 (4.0)
Fall 9 (6.6) 7 (5.6) 7 (4.7)
Hypertension 3 (2.2) 8 (6.4) 6 (4.0)
Nausea 8 (5.9) 8 (6.4) 5 (3.3)
Headache 9 (6.6) 6 (4.8) 6 (4.0)
Insomnia 3 (2.2) 10 (8.0) 2 (1.3)
Urinary tract infection 2 (1.5) 3 (2.4) 9 (6.0)
Abbreviation: PD, Parkinson disease.
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Discussion
In thisphase3study,once-daily treatmentwithopicaponewas
well tolerated and was associated with significant therapeu-
tic benefits in patients with PD who experienced motor fluc-
tuations, despite current treatment with levodopa and other
adjunct PD medications. The change from baseline in abso-
lute off-time at the end of the double-blind phase showed a
significant improvement compared with placebo in the 50-
mg/d opicapone group, and the benefits of off-time reduc-
tion were sustained throughout the 1-year open-label phase.
Althoughwe foundgreater reductionsof off-timewith the25-
mg/dopicaponegroup, the treatmentdifferenceswerenot sig-
nificant compared with the placebo group. This finding may
result from the higher-than-expected placebo effects that oc-
curred in this study. The sample size of 135 patients per arm
was calculated under the assumption of a much lower pla-
cebo response (30minutes) thanwas actually achieved (64.5
minutes), suggesting that the study may have been under-
powered to detect differences between groups.
The present results are similar to those of another phase 3
study,21 which also showed that treatmentwith opicapone ef-
fectively reduced off-time and increased on-time without in-
creasingthefrequencyof troublesomedyskinesia. Inthatstudy,
the50-mg/ddosagewasalsodemonstrated tobenoninferior to
adjunctentacaponetreatment,whichwas includedasanactive
comparator.21 Likewise, the reductions in off-time seen in the
present studyalsocomparewellwith thoseofother studies22-25
of adjunct therapy formotor complications in PD. Patients re-
ceiving the 50-mg/d dosage had amean off-time reduction of
54.3minutes vs placebo,which is higher than themean of 0.6
hour (36minutes) reported for the entacapone studies (which
hadbroadly similar studydesigns to this study),3 andwhich is
moresimilar tooff-timereductions reported forotheradjuvant
treatments suchasdopamineagonists.3,26Thesimilarityof the
phase 3opicapone trial designswill allowmeta-analyses of ef-
fect sizes tobeperformed, facilitatingourunderstandingtheef-
ficacy of opicapone in all outcomemeasures.
Although UPDRS motor function and other scale-based
measures, including nonmotor symptoms and quality of
life, all improvedduring thedouble-blindphase,we foundno
significantdifferences betweengroups. This resultmaybebe-
cause the patients were already receiving levodopa treat-
ment for symptomatic control and the study was only de-
signed and powered to address a potential differentiation in
motor fluctuations. By the endof the open-label phase,mean
PDSS, NMSS, and PDQ-39 scores maintained an overall im-
provement relative to thedouble-blindbaseline scores (eTable
3 in Supplement 2). Because patientswith PD andmotor fluc-
tuationsoften require frequentmedication changes, it is note-
worthy thatmost patientsmaintained the levodopa dose and
dosing frequency from the endof the titrationphase through-
out the duration of the study,which can be considered an ad-
ditional indicator of sustained control of motor fluctuations
during the long term.
Opicapone was well tolerated with no apparent dose-
relationship for themost of the adverse events. In thedouble-
blindphase, themost commonadverseevents associatedwith
opicaponetreatment (dyskinesia, constipation,anddrymouth)
reflectedgreaterdopaminergic availability. Toxic effects to the
liver have prevented the clinical use of tolcapone and devel-
opment of other COMT inhibitors.We therefore are reassured
that no relevant liver issues were observed with opicapone.
Similarly, diarrheahas been considered a class effect of COMT
inhibition,27,28 but this adverse event was absent from both
phases of the study, and no cases of severe diarrhea were re-
ported with opicapone treatment. The continued tolerability
of the drug during the open-label phase is supported by the
low rate of patientswhoprematurelywithdrewbecause of an
adverse event (32 patients).
Conclusions
Treatmentwithopicaponeeffectively reducedoff-timeand in-
creased on-timewithout increasing the frequency of trouble-
some dyskinesia, and this benefit wasmaintained for at least
1 year of therapy without increasing the levodopa dose. The
magnitudeof treatmenteffectwith the50-mg/ddosageofopi-
capone is considered clinically relevant,29 with approxi-
mately 1 hour of reduction in off-time. The simplicity af-
forded by the once-daily administrationmeans that addition
of this drug will not further complicate the patients’ current
drug regimen, while allowing more sophisticated adjust-
ments to the levodopa regimen that are harder to achieve, in
practice,whengiving levodopa inacombinedpillwithaCOMT
inhibitor (even taking into consideration the number of dose
availabilities for the combinedpill).When combinedwith the
favorable safety and tolerability profile, these characteristics
positionopicaponeas a strong candidate for the adjunct treat-
ment of motor fluctuations in PD.
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